Close Menu

Human Genome Sciences plans to release late-stage clinical data on Benlysta, its experimental drug for lupus, on Monday, reports Dow Jones Newswires. The story adds that lupus is "a notoriously hard-to-treat autoimmune disease that hasn't seen a new therapy in decades." Human Genome Sciences partnered with GlaxoSmithKline and worked closely with FDA to design its phase III trial after the phase II trial failed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.